Latest News
REDEFINE 4: CagriSema Weight Loss Results Compared With Tirzepatide
CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA). The
Trending Topics
- Opinion: Policymakers Must Prioritize Access to Innovative Obesity Treatments
- WHO Conditionally Recommends GLP-1s for Long-Term Obesity Care
- Trimming Obesity: A Vital Step Forward In Disease Prevention
- Semaglutide 2.4 mg Improves Insulin Sensitivity in Adolescents With Obesity
- Obesity Science and Practice Requires 5A Approach